APA (7th ed.) Citation

Zeng, X., Yu, J., Wu, X., Chen, Y., Wu, J., Yang, X., . . . Cao, G. (2022). Comparative assessment of pharmacokinetic parameters between HS016, an adalimumab biosimilar, and adalimumab (Humira®) in healthy subjects and ankylosing spondylitis patients: Population pharmacokinetic modeling. Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 31(5), 499-509. https://doi.org/10.17219/acem/145947

Chicago Style (17th ed.) Citation

Zeng, Xiaofeng, Jicheng Yu, Xiaojie Wu, Yuancheng Chen, Jufang Wu, Xiaoli Yang, Jingjing Wang, Jing Zhang, and Guoying Cao. "Comparative Assessment of Pharmacokinetic Parameters Between HS016, an Adalimumab Biosimilar, and Adalimumab (Humira®) in Healthy Subjects and Ankylosing Spondylitis Patients: Population Pharmacokinetic Modeling." Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University 31, no. 5 (2022): 499-509. https://doi.org/10.17219/acem/145947.

MLA (9th ed.) Citation

Zeng, Xiaofeng, et al. "Comparative Assessment of Pharmacokinetic Parameters Between HS016, an Adalimumab Biosimilar, and Adalimumab (Humira®) in Healthy Subjects and Ankylosing Spondylitis Patients: Population Pharmacokinetic Modeling." Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University, vol. 31, no. 5, 2022, pp. 499-509, https://doi.org/10.17219/acem/145947.